

Cardiovascular 2016-2017 Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that Committee members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by Committee members, NQF is requiring the following recusals be made during the measure evaluation period.

Measures Under Review & Committee Member Recusals

Measure Number	Measure Title	Measure Steward	Committee Member Recusals
#0066	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	AHA	<ul style="list-style-type: none"> Michael Crouch, MD, MSPH, FAAFP, Research Director and Quality Improvement Program Director, Memorial Family Medicine Residency Program and Associate Clinical Professor of Family Medicine, Texas A & M University School of Medicine Thomas James, MD, Chief Medical Officer, Baptist Health Plan and Baptist Health Community Care Sana Al-Khatib, MD, MHS, Associate Professor of Medicine, Duke University Medical Center
#2906	Coronary Artery Disease (CAD): Beta-Blocker Therapy- Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	AMA-PCPI	<ul style="list-style-type: none"> Michael Crouch, MD, MSPH, FAAFP, Research Director and Quality Improvement Program Director, Memorial Family Medicine Residency Program and Associate Clinical Professor of Family Medicine, Texas A & M University School of Medicine Thomas James, MD, Chief Medical Officer, Baptist Health Plan and Baptist Health Community Care